targets:
- name: CCR8
  description: CCR8 타겟 임상시험 모니터링
  trials:
  - id: NCT05101070
    name: S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor
      in Advanced or Metastatic Solid Tumors
  - id: NCT07362186
    name: LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the
      Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction
      Adenocarcinoma
  - id: NCT06387628
    name: LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent
      or Metastatic Triple - Negative Breast Cancer
  - id: NCT07213882
    name: A Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation
      Clinical Trial of Domain Therapeutics' Anti-CCR8 Monoclonal Antibody (DT-7012)
      in Patients With Relapsed or Refractory Cutaneous T-cell Lymphomas (CTCL)
  - id: NCT05537740
    name: A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8
      Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it
      Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find
      the Best Dose in Participants With Advanced Solid Tumors
  - id: NCT05007782
    name: Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults
      With Advanced Solid Tumors
  - id: NCT07205718
    name: A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors
  - id: NCT05635643
    name: Study of CHS-114 in Participants With Advanced Solid Tumors
  - id: NCT05935098
    name: BGB-A3055 Alone and in Combination With Tislelizumab in Participants With
      Solid Tumors
  - id: NCT06657144
    name: A Study of CHS-114 in Combination With Toripalimab and/or Other Treatments
      in Participants With Advanced Solid Tumors
  - id: NCT06620822
    name: 'Efficacy of PD-1 Inhibitor Combination Therapy in Non-small Cell Lung Cancer
      Patients Who Have Not Achieved Major Pathologic Response After Neoadjuvant Immunotherapy:
      a Multicenter, Phase II Clinical Trial'
  - id: NCT07226856
    name: BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel
      for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma
- name: TIGIT
  description: TIGIT 타겟 임상시험 모니터링
  trials:
  - id: NCT04818619
    name: TIGIT in Patients With Chronic Myeloid Leukemia
  - id: NCT04150965
    name: Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT
  - id: NCT05607563
    name: A Study of PM1009 (Anti-TIGIT/PVRIG) in Patients With Advanced Tumours
  - id: NCT05394168
    name: A Phase I Clinical Study of HLX53 in Advanced/Metastatic Solid Tumors
  - id: NCT07171307
    name: 'Treg Effector Function and Th2/Treg Ratio in Allergic Conjunctivitis: Effect
      of Desensitization Therapy'
  - id: NCT04995523
    name: A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants
      With Advanced or Metastatic NSCLC
  - id: NCT03119428
    name: A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid
      Tumors
  - id: NCT04500678
    name: Impact of Metformin on Immuno-virologic Parameters in HIV
  - id: NCT05483400
    name: Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid
      Tumors
  - id: NCT05390528
    name: A Study Evaluating the Safety, Tolerability, Pharmacokinetic and Efficacy
      of HLX301(TIGIT×PDL1 Bispecific) in Locally Advanced/Metastatic Solid Tumors
      or Lymphoma
  - id: NCT06250036
    name: Zimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer
  - id: NCT05653284
    name: A Study of AK130 in Patients With Advanced Malignant Tumors
  - id: NCT05102214
    name: HLX301 (TIGIT×PDL1 Bispecific) in Patients With Locally Advanced or Metastatic
      Solid Tumors
  - id: NCT05023109
    name: GP Chemotherapy in Combination With Anti-PD-1 and Anti-TIGIT in Unresectable
      Advanced BTC
  - id: NCT05130177
    name: Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory
      Melanoma
  - id: NCT04047862
    name: Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced
      Solid Tumors
  - id: NCT05537051
    name: A Study of PM1021 (Anti-TIGIT) With or Without PM8001 (Anti-PD-L1/TGF-β)
      in Patients With Advanced Solid Tumours
  - id: NCT05019677
    name: GP Chemotherapy in Combination With Tislelizumab and Ociperlimab as First-line
      Treatment in Advanced BTC
  - id: NCT05061628
    name: The Recombinant Humanized Anti-TIGIT Monoclonal Antibody (JS006) Monotherapy
      and in Combination With Toripalimab in Patients With Advanced Tumor
  - id: NCT04656535
    name: AB154 Combined With AB122 for Recurrent Glioblastoma
  - id: NCT06773507
    name: Phase I Study of BC008-1A Injection in Patients With Advanced Solid Tumors
  - id: NCT06349980
    name: A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety
      and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally
      Advanced or Metastatic Hepatocellular Carcinoma Patients.
  - id: NCT05706207
    name: A Study of HB0030 Injection in Patients With Advanced Solid Tumors
  - id: NCT05060432
    name: Study of EOS-448 With Standard of Care and/or Investigational Therapies
      in Participants With Advanced Solid Tumors
  - id: NCT06713798
    name: Targeting PD-L1 and TIGIT in Tumors With Tertiary Lymphoid Structures
  - id: NCT05394337
    name: Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible
      Operable High-Risk Urothelial Carcinoma
  - id: NCT05253105
    name: A Clinical Study of TAB006 in Patients With Previously Treated, Advanced
      Malignancies
  - id: NCT04270942
    name: At-Risk for Type 1 Diabetes Extension Study (TN-10 Extension)
  - id: NCT05294952
    name: co Ihibtory Receptor in Preeclampsia
  - id: NCT06754501
    name: A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune
      Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab)
      in Cancer of Unknown Primary
  - id: NCT05757492
    name: Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab
      in Patients With Advanced Solid Tumors
  - id: NCT04952597
    name: Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants
      With Untreated Limited-Stage Small Cell Lung Cancer
  - id: NCT05805501
    name: A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants
      With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
  - id: NCT03447678
    name: Pembrolizumab in First Line Treatment of Advanced NSCLC Patients With PD-L1
      Low Tumors.
  - id: NCT04672369
    name: A Study to Evaluate the Efficacy of IBI939 in Combination With Sintilimab
      in Patients With Advanced NSCLC
  - id: NCT04672356
    name: A Study to Evaluate the Safety , Tolerability and Efficacy of IBI939 in
      Combination With Sintilimab in Patients With Advanced Lung Cancer
  - id: NCT05009069
    name: A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant
      Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer
  - id: NCT04353830
    name: A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant
      Human Anti-T-cell Immunoreceptor With Ig and ITIM Domains (TIGIT) Monoclonal
      Antibody Injection (IBI939) in Subjects With Advanced Malignant Tumors
  - id: NCT07337447
    name: Trial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI With a Hybrid
      Synthetic Control Arm in Second Line Treatment of Neuroendocrine Carcinoma of
      Gastro-enteropancreatic or Unknown Origin (REWENEC 01)
  - id: NCT04354246
    name: COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
  - id: NCT04933227
    name: A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab
      and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic
      Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)
  - id: NCT05414032
    name: Molecular Residual Disease Interception in Locoregionally-Advanced High
      Risk HPV+ and HPV- HNSCC
  - id: NCT06003621
    name: Tiragolumab and Atezolizumab in Advanced Pan-cancer Patients
  - id: NCT05568095
    name: A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab,
      Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That
      Cannot be Removed With Surgery That Has Spread to Other Parts of the Body
  - id: NCT06777628
    name: Immunophenotype of PBMC to Early Predict Response to Immunotherapy in Hepatocellular
      Carcinoma
  - id: NCT06773481
    name: BC008-1A Injection for Recurrent CNS WHO G4 Glioma
  - id: NCT03708224
    name: Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the
      Head and Neck
  - id: NCT03652402
    name: Precision Risk Stratification in Kidney Transplant Patients - EU-TRAIN
  - id: NCT03486119
    name: A Study for Identification of Predictive Immune Biomarker in Peripheral
      Blood for Nivolumab Therapy in NSCLC Patients
  - id: NCT05120375
    name: Assessment of Safety and Preliminary Efficacy With BAT6021 in Solid Tumor
      Patients in China
  - id: NCT05327530
    name: A Study of the Safety and Efficacy of Various Combinations of Avelumab as
      Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder
      Medley)
  - id: NCT04570839
    name: COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced
      Solid Tumors.
  - id: NCT05520294
    name: Evaluating the Effects of Cannabis Use and Circulating Cannabinoids on Tumor
      Infiltrating Lymphocytes in Malignant Melanoma
  - id: NCT05417321
    name: A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced
      Solid Tumors
  - id: NCT06328036
    name: Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab
      to Improve Outcomes for Patients With Recurrent Glioblastoma
  - id: NCT04465643
    name: Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral
      Nerve Sheath Tumor
  - id: NCT04262856
    name: Study to Evaluate Monotherapy and Combination Immunotherapies in Participants
      With PD-L1 Positive Non-small Cell Lung Cancer
  - id: NCT04736173
    name: Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab
      in Lung Cancer
  - id: NCT05126537
    name: Co-inhibitory Molecules on Treg and miR-155-5p in Patients With Sepsis
  - id: NCT05289492
    name: Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma
  - id: NCT07115043
    name: A Study to Investigate Safety of AZD6750 in Adult Participants With Select
      Advanced or Metastatic Solid Tumors
  - id: NCT05743504
    name: Immunotherapy With CCRT Followed by Surgery for Locally Advanced ESCC Patients
  - id: NCT05073484
    name: Assessment of Safety and Preliminary Efficacy With BAT6021 in Solid Tumor
      Patients
  - id: NCT07376512
    name: Predicting Response to Anti-PD-1/PD-L1 Immunotherapy by Plasma Extracellular
      Vesicle Analysis
  - id: NCT05904886
    name: A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab,
      in Participants With Untreated Locally Advanced or Metastatic Hepatocellular
      Carcinoma (HCC) (IMbrave152)
  - id: NCT03739710
    name: Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants
      With Non-small Cell Lung Cancer (NSCLC)
  - id: NCT04791839
    name: Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab
      (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small
      Cell Lung Cancer
  - id: NCT05020912
    name: Alteration of the Immune Microenvironment in Basal Cell Carcinoma Following
      Photodynamic Therapy
  - id: NCT06334406
    name: Antitumor T Cell Responses in Patients With Bladder Cancer
  - id: NCT07343310
    name: A First-in-Patient Clinical Trial of KINE-101 in Patients With Corticosteroid-Refractory
      CIDP
  - id: NCT03342417
    name: Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer
      Patients
  - id: NCT04682665
    name: Prebiotic Effect of Eicosapentaenoic Acid Treatment for Colorectal Cancer
      Liver Metastases
  - id: NCT05123482
    name: A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants
      With Advanced/Metastatic Solid Malignancies
  - id: NCT07161414
    name: A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig
      in Adult Participants With Advanced Solid Tumors Previously Treated With Standard
      of Care Therapy
  - id: NCT07015164
    name: Role of Viral Reservoir, Immune Activation and Depletion in Persistent Viremia
      Persistent Viremia in People Living With HIV on Antiretroviral Therapy
  - id: NCT05702229
    name: Novel Combinations in Participants With Locally Advanced Unresectable or
      Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
  - id: NCT07213882
    name: A Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation
      Clinical Trial of Domain Therapeutics' Anti-CCR8 Monoclonal Antibody (DT-7012)
      in Patients With Relapsed or Refractory Cutaneous T-cell Lymphomas (CTCL)
  - id: NCT03628677
    name: A Study to Evaluate the Safety and Tolerability of AB154 in Participants
      With Advanced Malignancies
  - id: NCT06897436
    name: Characterization of Immune Cells and Their Secreted Cytokines in Endometriosis
      Patients
  - id: NCT05633927
    name: Humoral and Cellular Immunity Against SARS-COV-2 Vaccine in HIV-infected
      Patients Immunosuppressed
  - id: NCT04836507
    name: Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma Patients
  - id: NCT05775159
    name: Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer
      Agents in Participants With Advanced Hepatobiliary Cancer
  - id: NCT06338657
    name: FID-007 Followed by Standard of Care Surgery in Head and Neck Cancer
  - id: NCT06860815
    name: Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for
      the Treatment of Liver Directed Metastatic Breast Cancer
  - id: NCT04624828
    name: Immune Response Evaluation in Oligorecurrent and Oligoprogressive Prostate
      Cancer Patients Treated With SBRT
  - id: NCT05574335
    name: Siplizumab in T1DM
  - id: NCT06302556
    name: The Role of Immune Checkpoints in Lung Transplant (ILTRA)
  - id: NCT04761198
    name: A Study of Etigilimab and Nivolumab in Participants With Locally Advanced
      or Metastatic Tumors
  - id: NCT04693234
    name: 'AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined
      With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants
      With Previously Treated Recurrent or Metastatic Cervical Cancer'
  - id: NCT03563716
    name: A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve
      Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
  - id: NCT07324642
    name: A Phase 1 MAD Study of KINE-101 in Healthy Volunteers
  - id: NCT05809895
    name: Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination
      With Tislelizumab and Chemotherapy as First-line Treatment for Participants
      With Advanced Triple Negative Breast Cancer
  - id: NCT04732494
    name: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without
      Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With
      Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
  - id: NCT05645692
    name: A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without
      TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced
      Metastatic Urothelial Cancer
  - id: NCT04457778
    name: First in Human Study of M6223
  - id: NCT03772899
    name: Fecal Microbial Transplantation in Combination With Immunotherapy in Melanoma
      Patients (MIMic)
  - id: NCT04374877
    name: Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid
      Tumors
  - id: NCT06346197
    name: Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR
      Esogastric Adenocarcinomas
  - id: NCT05780073
    name: Safety and Impact of Dasatinib on Viral Persistence and Inflammation in
      People With HIV Under Antiretroviral Treatment
  - id: NCT03667716
    name: COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
  - id: NCT06784947
    name: Trial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients With Microsatellite
      Stable, Metastatic Colorectal Cancer
  - id: NCT05014815
    name: Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated
      Metastatic Non-Small Cell Lung Cancer
  - id: NCT07307053
    name: Rare Tumor Focused Platform Study of Innovative Therapies and Technologies
      (PLATFORM2)
  - id: NCT04746924
    name: A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants
      With Untreated Lung Cancer
  - id: NCT07098338
    name: A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
  - id: NCT06532539
    name: Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial
      Carcinoma
  - id: NCT06864598
    name: The Application of Novel Identified CD8 Regulatory Precursors in Inducing
      Immune Tolerance After Allo-HSCT
  - id: NCT03661047
    name: OMega-3 Fatty Acid for the Immune Modulation of Colorectal Cancer
  - id: NCT04866017
    name: A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following
      Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable
      Non-Small Cell Lung Cancer
  - id: NCT05127824
    name: Autologous Dendritic Cell Vaccine in Kidney Cancer
  - id: NCT04303169
    name: 'Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With
      Investigational Agents or Pembrolizumab Alone in Participants With Stage III
      Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)'
  - id: NCT05329766
    name: A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy
      in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies
  - id: NCT04323202
    name: Neoadjuvant-Adjuvant Pembrolizumab in Resectable Advanced Basal Cell Carcinoma
      of H&N
  - id: NCT07221253
    name: A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line
      Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
  - id: NCT05676931
    name: Study With Various Immunotherapy Treatments in Participants With Lung Cancer
  - id: NCT06790706
    name: 'IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated
      by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy
      With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE
      Cancers'
  - id: NCT04543617
    name: A Study of Atezolizumab With or Without Tiragolumab in Participants With
      Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed
      Following Definitive Concurrent Chemoradiotherapy
  - id: NCT04305041
    name: 'Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With
      Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory
      Melanoma (MK-3475-02A/KEYMAKER-U02)'
  - id: NCT06996782
    name: A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
  - id: NCT05665595
    name: A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab
      for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma
      (MK-7684A-010/KEYVIBE-010)
  - id: NCT06868277
    name: A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for
      First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
  - id: NCT06692738
    name: A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy
      for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
  - id: NCT04774484
    name: High-Intensity Interval Training and Regulatory T Cells
  - id: NCT04256421
    name: A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab
      in Patients With Untreated Extensive-Stage Small Cell Lung Cancer
  - id: NCT06989112
    name: 'DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus
      Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC
      3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer'
  - id: NCT05816460
    name: The Sleepio After Cancer Study
  - id: NCT06627647
    name: A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy
      for First-Line Treatment of Metastatic Non-squamous NSCLC
  - id: NCT04305054
    name: 'Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With
      Investigational Agents or Pembrolizumab Alone in Participants With First Line
      (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)'
  - id: NCT04294810
    name: A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo
      in Combination With Atezolizumab in Patients With Previously Untreated Locally
      Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer
  - id: NCT03198546
    name: GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression
  - id: NCT03198052
    name: GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T
      Cells Against Cancers
  - id: NCT04585815
    name: Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies
      in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)
  - id: NCT02443155
    name: A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed
      Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide
      on Preservation of Beta-cell Function
- name: IgE
  description: 그냥 테스트용
  trials:
  - id: NCT02546921
    name: Phase I Study of MOv18 IgE
  - id: NCT03019237
    name: Effect of Intranasal Anti-IgE Antibodies on IgE Production
  - id: NCT06547840
    name: A Study of MOv18 IgE in Folate Receptor Alpha-expressing Platinum Resistant
      Ovarian Cancer
- name: B7-H3
  description: B7-H3 타겟 임상시험 모니터링
  trials:
  - id: NCT07358260
    name: B7-H3.CD28Z.CART in Solid Tumors
  - id: NCT06500819
    name: Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory
      Solid Tumors
  - id: NCT05515185
    name: B7-H3 Targeting CAR-T Cells Therapy for B7-H3 Positive Solid Tumors
  - id: NCT06778603
    name: B7-H3 NIR Imaging for Osteosarcoma Surgery
  - id: NCT05942456
    name: Soluble B7-H3 as a Biomarker for Osteosarcoma
  - id: NCT04077866
    name: B7-H3 CAR-T for Recurrent or Refractory Glioblastoma
  - id: NCT05474378
    name: B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Recurrent Glioblastoma
      Multiforme
  - id: NCT04897321
    name: B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric
      Patients With Solid Tumors (3CAR)
  - id: NCT06158139
    name: Autologous CAR-T Cells Targeting B7-H3 in PDAC
  - id: NCT04385173
    name: Pilot Study of B7-H3 CAR-T in Treating Patients With Recurrent and Refractory
      Glioblastoma
  - id: NCT05835687
    name: 'Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients
      With Primary CNS Tumors'
  - id: NCT02628535
    name: Safety Study of MGD009 in B7-H3-expressing Tumors
  - id: NCT07222735
    name: Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric
      Patients With Relapsed/Refractory Sarcomas
  - id: NCT06018363
    name: Clinical Study on the Treatment of Malignant Brain Glioma by QH104 Cell
      Injection
  - id: NCT06646627
    name: Clinical Trial of Autologous B7-H3 CAR T Cells in Reoccurent Platinum-resistant
      Ovarian Tumors
  - id: NCT06347068
    name: Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T
      Cells
  - id: NCT04432649
    name: Targeting CD276 (B7-H3) Positive Solid Tumors by 4SCAR-276
  - id: NCT02982941
    name: Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors
  - id: NCT05562024
    name: TAA06 Injection in the Treatment of Patients With B7-H3-positive Relapsed/
      Refractory Neuroblastoma
  - id: NCT04670068
    name: Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent
      Epithelial Ovarian
  - id: NCT05241392
    name: Safety and Efficacy Study of Anti-B7-H3 CAR-T Cell Therapy for Recurrent
      Glioblastoma
  - id: NCT03406949
    name: MGD009/MGA012 Combination in Relapsed/Refractory Cancer
  - id: NCT05366179
    name: Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc
  - id: NCT07172958
    name: Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory
      Embryonal Tumors (SABRE)
  - id: NCT06454955
    name: Study on B7-H3 Targeted Affibody Radioligand Probes for PET Imaging of Solid
      Tumors
  - id: NCT05752877
    name: Safety and Efficacy of Targeted IL-13 Rα2 or B7-H3 UCAR-T for Advanced Glioma
  - id: NCT05190185
    name: A Clinical Trial of TAA06 Injection in Advanced Solid Tumors
  - id: NCT03198052
    name: GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T
      Cells Against Cancers
  - id: NCT06951243
    name: A Trial of MHB088C in Advanced Extrapulmonary Neuroendocrine Cancer
  - id: NCT06305299
    name: Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T
      Cells
  - id: NCT07189871
    name: 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable,
      or Metastatic Solid Tumors
  - id: NCT05731219
    name: UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
  - id: NCT06169904
    name: B7-Family Score in Urothelial Carcinoma
  - id: NCT02381314
    name: Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in
      Refractory Cancer
  - id: NCT01918930
    name: Tissue Procurement Substudy for Participants in Study CP-MGA271-01
  - id: NCT05722171
    name: Clinical Study of UTAA06 Injection in the Treatment of Relapsed/Refractory
      Acute Myeloid Leukemia
  - id: NCT07268053
    name: A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted
      Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and
      Patients With Brain Metastases
  - id: NCT05143151
    name: CD276-targeted Chimeric Antigen Receptor T Cells in Treatment With Advanced
      Pancreatic Cancer
  - id: NCT04315246
    name: 177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From
      Solid Tumors (Breast, NSCLC, Malignant Melanoma)
  - id: NCT04185038
    name: Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse
      Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory
      Pediatric Central Nervous System Tumors
  - id: NCT07099898
    name: A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer
      (SCLC)
  - id: NCT04167618
    name: 177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma
  - id: NCT05768880
    name: Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional
      Immunotherapy For Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline
      Glioma, And Recurrent Or Refractory Central Nervous System Tumors
  - id: NCT06699576
    name: 'ARTEMIS-103: Phase 1b Study of HS-20093 Combinations in Patients with Bone
      and Soft Tissue Sarcoma.'
  - id: NCT06825624
    name: 'ARTEMIS-102: HS-20093 Combinations in Patients with Advanced Metastatic
      Colorectal Cancer'
  - id: NCT06112704
    name: HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced
      Solid Tumors
  - id: NCT05280470
    name: Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage
      Small Cell Lung Cancer (ES-SCLC)
  - id: NCT06912152
    name: MT027 in Patients With Advanced Peritoneal Malignancies or Abdominal Metastatic
      Solid Tumors
  - id: NCT06426680
    name: A Study of the ILB-3101 in Patients with Advanced Solid Tumors
  - id: NCT02475213
    name: Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab
      or MGA012 in Refractory Cancer
  - id: NCT06482905
    name: Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive
      Grade 4 Glioma.
  - id: NCT06892548
    name: A Clinical Study to Investigate the Efficacy and Safety of an Investigational
      Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
  - id: NCT04129320
    name: Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head
      and Neck
  - id: NCT07256782
    name: A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors
  - id: NCT03729596
    name: MGC018 With or Without MGA012 in Advanced Solid Tumors
  - id: NCT06332170
    name: 'ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced
      Solid Tumors'
  - id: NCT05830123
    name: 'ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma
      and Other Sarcomas'
  - id: NCT02456571
    name: CTC Immune Checkpoint
  - id: NCT07115446
    name: Phase Ib Study of HS-20093+HRS-5041 in Patients With Advanced Prostate Cancer
  - id: NCT06203210
    name: A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice
      in Subjects With Relapsed Small Cell Lung Cancer
  - id: NCT06007729
    name: 'ARTEMIS-006: HS-20093 in Patients With Head and Neck Squamous Cell Carcinoma
      and Other Solid Tumors'
  - id: NCT04637503
    name: 4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma
  - id: NCT06052423
    name: 'ARTEMIS-007: HS-20093 in Patients With Extensive Stage Small Cell Lung
      Cancer'
  - id: NCT06242470
    name: A Study of MGC026 in Participants With Advanced Solid Tumors
  - id: NCT06780137
    name: A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab
      Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage
      Small Cell Lung Cancer (MK-6070-002)
  - id: NCT05276609
    name: 'ARTEMIS-001: Phase 1 Study of the HS-20093 in Patients With Advanced Solid
      Tumors'
  - id: NCT07227597
    name: A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400)
      in People With Small Cell Lung Cancer (MK-6070-003)
  - id: NCT07386002
    name: A Phase II Study of Intracerebroventricular MT027 in Recurrent or Progressive
      Glioblastoma
  - id: NCT05063357
    name: 131I-omburtamab Delivered by Convection-Enhanced Delivery in Patients With
      Diffuse Intrinsic Pontine Glioma
  - id: NCT06776198
    name: Precision Therapy Based on Immune Microenvironment by Transcriptome Sequencing
      of Osteosarcoma, a Prospective, Multi-cohort Exploratory Clinical Study
  - id: NCT04842812
    name: Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors
  - id: NCT06001255
    name: 'ARTEMIS-003: HS-20093 in Patients With Metastatic Castrate-resistant Prostate
      Cancer (mCRPC) and Advanced Solid Tumors'
  - id: NCT06330064
    name: A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd)
      In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)
  - id: NCT07231081
    name: Phase I Study of TX103 CAR-T Cells in Participants With Advanced Solid Tumors
  - id: NCT05064306
    name: 131I-omburtamab for the Treatment of Central Nervous System/Leptomeningeal
      Neoplasms in Children and Young Adults
  - id: NCT05142189
    name: Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy
      of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell
      Lung Cancer
  - id: NCT06362252
    name: A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin
      as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small
      Cell Lung Cancer (IDeate-Lung03)
  - id: NCT06372236
    name: UTAA06 Injection for Treatment of Advanced Malignant Solid Tumors
  - id: NCT06954246
    name: A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects
      With Relapsed Small Cell Lung Cancer
  - id: NCT04634825
    name: Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer
  - id: NCT05991583
    name: A Clinical Trial to Evaluate Effect of IBB0979 in Patients With Advanced
      Malignant Tumors
  - id: NCT07076095
    name: A Phase II/III Study of IBB0979 in Combination With Topotecan Versus Topotecan
      in Relapsed Small Cell Lung Cancer
  - id: NCT04864821
    name: Clinical Study of CD276 Targeted Autologous Chimeric Antigen Receptor T
      Cell Infusion in Patients With CD276 Positive Advanced Solid Tumor
  - id: NCT05914116
    name: A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
  - id: NCT07004647
    name: MT027 Cell Injection in Patients With Advanced Primary or Secondary Peritoneal
      Tumors
  - id: NCT07181473
    name: A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in
      Patients With Advanced/Metastatic Solid Tumors
  - id: NCT05293496
    name: A Study of MGC018 in Combination With MGD019 in Participants With Advanced
      Solid Tumors
  - id: NCT06742593
    name: Study of MT027 in Patients with Brain, Meninges, and Spinal Cord Metastatic
      Solid Tumors
  - id: NCT04630769
    name: FT516 and IL2 With Enoblituzumab for Ovarian Cancer
  - id: NCT04544592
    name: UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL
  - id: NCT02883595
    name: Efficacy of Thymosin Alpha 1 on Improving Monocyte Function for Sepsis
  - id: NCT00554515
    name: The High-Dose Aldesleukin (IL-2) "Select" Trial for Patients With Metastatic
      Renal Cell Carcinoma
  - id: NCT02204020
    name: Phase II Study of 5-azacytidine Maintenance After Transplant for AML or
      MDS
  - id: NCT02937844
    name: Pilot Study of Autologous Chimeric Switch Receptor Modified T Cells in Recurrent
      Glioblastoma Multiforme
  - id: NCT06644781
    name: A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or
      Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
  - id: NCT05562869
    name: Belatacept as a Replacement for CNIs 3 to 12 Months Post-transplantation
      in Patients With Early Graft Dysfunction
  - id: NCT04013620
    name: CNI Transient Replacement by Belatacept From 3 to 12 Months Post Transplantation
      in Patients With Early Graft Dysfunction
  - id: NCT04276701
    name: Immune Mediators and Metabolites to Stratify Systemic Lupus Erythematosus
      Patients at High Risk of Cardio Vascular Diseases
  - id: NCT07136558
    name: Evaluation of ICP-B794 in Patients With Advanced Solid Tumors
  - id: NCT06953089
    name: DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid
      Tumors
  - id: NCT02584517
    name: Aetiology of TemporaL Arteritis Study
  - id: NCT07307053
    name: Rare Tumor Focused Platform Study of Innovative Therapies and Technologies
      (PLATFORM2)
  - id: NCT06993766
    name: The Predictability of CD19 Expression Across Primitive Cellular Fractions
      of Relapsed B-ALL on Outcomes of CD19-targeted CAR T-cells
  - id: NCT02923180
    name: Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and
      High-Risk Prostate Cancer
  - id: NCT06014255
    name: Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized
      Prostate Cancer
  - id: NCT04465643
    name: Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral
      Nerve Sheath Tumor
  - id: NCT06221553
    name: Safety and Efficacy of Loco-regional B7H3 IL-7Ra CAR T Cell in DIPG
  - id: NCT06612645
    name: Safety and Efficacy of CMD03 CAR T Cell in Children With Relapse or Refractory
      Solid Tumors
  - id: NCT04514484
    name: Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and
      Nivolumab in Patients With Advanced Cancer and HIV
  - id: NCT04743661
    name: 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma
  - id: NCT03014804
    name: Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and
      Nivolumab in Treating Patients With Recurrent Glioblastoma
